［1］LOUIS D N, OHGAKI H, WIESTLER O D, et al. The 2007 WHO classification of tumours of the central nervous system［J］. Acta Neuropathol, 2007,114(2):97-109.
［2］LOUIS D N, PERRY A, REIFENBERGER G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary［J］. Acta Neuropathol, 2016,131(6):803-820.
［3］LOUIS D N, PERRY A, WESSELING P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary［J］. Neuro Oncol, 2021,23(8):1231-1251.
［4］SOEDA A, HARA A, KUNISADA T, et al. The evidence of glioblastoma heterogeneity［J］. Sci Rep, 2015,5:7979.
［5］AUM D J, KIM D H, BEAUMONT T L, et al. Molecular and cellular heterogeneity: the hallmark of glioblastoma［J］. Neurosurg Focus, 2014,37(6):E11.
［6］CHAMBERLAIN M C. Bevacizumab for the treatment of recurrent glioblastoma［J］. Clin Med Insights Oncol, 2011,5:117-129.
［7］LEE J H, XIONG F, LI W. Enhancer RNAs in cancer: regulation, mechanisms and therapeutic potential［J］. RNA Biol, 2020,17(11):1550-1559.
［8］CHEN B, KHODADOUST M S, LIU C L, et al. Profiling Tumor Infiltrating Immune Cells with CIBERSORT［J］. Methods Mol Biol, 2018,1711:243-259.
［9］QIAN B Z, POLLARD J W. Macrophage diversity enhances tumor progression and metastasis［J］. Cell, 2010,141(1):39-51.
［10］GORDON S, TAYLOR P R. Monocyte and macrophage heterogeneity［J］. Nat Rev Immunol, 2005,5(12):953-964.

［11］OLTMANNS U, ISSA R, SUKKAR M B, et al. Role of c-jun N-terminal kinase in the induced release of GM-CSF, RANTES and IL-8 from human airway smooth muscle cells［J］. Br J Pharmacol, 2003,139(6):1228-1234.
［12］任晓辉,林松,王忠诚.低级别胶质肿瘤的1p/19q缺失研究［J］.中国神经肿瘤杂志,2009,7(3):171-174.
［13］郑长青,季守平,宫锋,等.MGMT基因启动子甲基化检测在脑胶质瘤化疗中的意义［J］.癌症,2009,28(6):575-580.